#USA #Philadelphia #fiduciary duties #Baxter International #Novum LVP

Investigation into Baxter International Inc.'s Board of Directors

On November 25, 2025, Berger Montague PC, a prominent law firm, announced an investigation into Baxter International Inc. (NYSE: BAX) focusing on its Board of Directors and alleged breaches of fiduciary duties. The inquiry specifically pertains to the company’s marketing and sale practices related to the Novum Large Volume Pump (Novum LVP), a medical device vital for delivering intravenous fluids, including medication and nutrients.

Background on Baxter International Inc.

Baxter International Inc. has a long-standing reputation in the healthcare industry, known for providing innovative medical products, therapies, and services that enhance patient care. The Novum LVP was designed to meet the demands of modern healthcare settings, allowing for controlled, accurate delivery of intravenous treatments. With the increasing reliance on such devices, oversight and ethical marketing practices are more critical than ever in safeguarding patients and shareholders alike.

However, events took a concerning turn in July 2025 when Baxter announced a voluntary and temporary pause on shipments and installations of the Novum LVP. This decision raised red flags and prompted scrutiny regarding the company’s operational and marketing strategies. It is in this context that Berger Montague has initiated its investigation, aiming to determine if the Board acted in the best interests of its shareholders.

The Legal Framework of Fiduciary Duties

Fiduciary duties are legal obligations that require a company’s directors to act in good faith and prioritize the interests of the shareholders. This encompasses various responsibilities, including exercising due diligence in decision-making, providing accurate information, and avoiding conflicts of interest. If proven that Baxter’s Board failed to uphold these duties, the implications could range from financial penalties to reputational damage.

The investigation seeks to uncover whether the Board's oversight—or lack thereof—was detrimental to shareholders, particularly in the context of the Novum LVP. The firm is urging shareholders who may have concerns or further insights related to the Board’s actions to reach out.

Contact Information for Shareholders

Shareholders of Baxter International Inc. who want to learn more about the investigation can contact:

• - Radha Raghavan at [email protected] or (332) 271-8908
• - Andrew Abramowitz at [email protected] or (215) 875-3015

Detailed information and updates about the investigation can also be found on Berger Montague's website under the specific case on Baxter’s fiduciary responsibilities.

Implications of the Investigation

This investigation comes at a critical time, as investor confidence and public trust in healthcare companies are paramount, especially in the wake of increased scrutiny over corporate governance. As the healthcare industry navigates through technological advancements and patient care demands, maintaining ethical standards and accountability becomes essential.

Baxter’s Board may face serious challenges if the investigation confirms breaches of fiduciary duties, which could result in legal action, financial repercussions, and loss of investor trust. It is essential for the company to take proactive steps to address these issues and restore confidence among its stakeholders.

It is important to remember that investigations of this nature aim not only to hold individuals accountable but also to enhance corporate governance practices and ensure better protection of investors in the long run.

Conclusion

The unfolding situation with Baxter International Inc. presents a significant case for shareholders and the wider healthcare community. Stakeholders are encouraged to stay informed and engaged as the investigation progresses, ensuring that the highest ethical standards are upheld within the industry.